Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.
暂无分享,去创建一个
M. Maitland | A. Tolcher | S. Ou | P. LoRusso | Tianhong Li | L. P. Koplowitz | H. Ball | J. Park | E. Bahceci | G. Yuen